APA

Catenacci D. V. T., Tebbutt N. C., Davidenko I., Murad A. M., Al-Batran S., Ilson D. H., Tjulandin S., Gotovkin E., Karaszewska B., Bondarenko I., Tejani M. A., Udrea A. A., Tehfe M., De Vita F., Turkington C., Tang R., Ang A., Zhang Y., Hoang T., Sidhu R. & Cunningham D. (20171215). Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology.

Chicago

Catenacci Daniel V T, Tebbutt Niall C, Davidenko Irina, Murad André M, Al-Batran Salah-Eddin, Ilson David H, Tjulandin Sergei, Gotovkin Evengy, Karaszewska Boguslawa, Bondarenko Igor, Tejani Mohamedtaki A, Udrea Anghel A, Tehfe Mustapha, De Vita Ferdinando, Turkington Cheryl, Tang Rui, Ang Agnes, Zhang Yilong, Hoang Tien, Sidhu Roger and Cunningham David. 20171215. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology.

Harvard

Catenacci D. V. T., Tebbutt N. C., Davidenko I., Murad A. M., Al-Batran S., Ilson D. H., Tjulandin S., Gotovkin E., Karaszewska B., Bondarenko I., Tejani M. A., Udrea A. A., Tehfe M., De Vita F., Turkington C., Tang R., Ang A., Zhang Y., Hoang T., Sidhu R. and Cunningham D. (20171215). Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology.

MLA

Catenacci Daniel V T, Tebbutt Niall C, Davidenko Irina, Murad André M, Al-Batran Salah-Eddin, Ilson David H, Tjulandin Sergei, Gotovkin Evengy, Karaszewska Boguslawa, Bondarenko Igor, Tejani Mohamedtaki A, Udrea Anghel A, Tehfe Mustapha, De Vita Ferdinando, Turkington Cheryl, Tang Rui, Ang Agnes, Zhang Yilong, Hoang Tien, Sidhu Roger and Cunningham David. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. : The Lancet. Oncology. 20171215.